Treatment of Alzheimer's Disease
- 25 November 1999
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (22) , 1670-1679
- https://doi.org/10.1056/nejm199911253412207
Abstract
Alzheimer's disease, which is characterized by progressive loss of memory and cognitive function, affects 15 million people worldwide. The incidence increases steadily from 0.5 percent per year at the age of 65 years to nearly 8 percent per year after the age of 85 years.1 Because survival for a decade is common, the prevalence increases from 3 percent at the age of 65 years to 47 percent after the age of 85 years.2 Mutations in the gene for the amyloid precursor protein and the genes for presenilin 1 and 2 cause rare, dominantly inherited forms of the disease occurring before . . .Keywords
This publication has 98 references indexed in Scilit:
- Cholinesterase Inhibitors in the Treatment of Alzheimer??s DiseaseDrug Safety, 1998
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- Protective actions of l-carnitine and acetyl-l-carnitine on the neurotoxicity evoked by mitochondrial uncoupling or inhibitorsPharmacological Research, 1995
- An Intervention That Delays Institutionalization of Alzheimer's Disease Patients: Treatment of Spouse-CaregiversThe Gerontologist, 1993
- Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reportedPublished by American Medical Association (AMA) ,1989
- Intracerebroventricular bethanechol chloride infusion in Alzheimer's diseaseJournal of Neurosurgery, 1989
- Preliminary reportNeurosurgery, 1984
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Loxapine in PsychogeriatricsJournal of Clinical Psychopharmacology, 1982
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960